» Articles » PMID: 21037243

Health Outcomes in Economic Evaluation: the QALY and Utilities

Overview
Journal Br Med Bull
Specialty General Medicine
Date 2010 Nov 2
PMID 21037243
Citations 413
Authors
Affiliations
Soon will be listed here.
Abstract

The quality-adjusted life year (QALY) is routinely used as a summary measure of health outcome for economic evaluation, which incorporates the impact on both the quantity and quality of life. Key studies relating to the QALY and utility measurement are the sources of data. Areas of agreement include the need for a standard measure of health outcome to enable comparisons across different disease areas and populations, and the methods used for valuing health states in utility measurement. Areas of controversy include the limitation of the QALY approach in terms of the health benefits it can capture, its blindness towards equity concerns, the underlying theoretical assumptions and the most appropriate generic preference-based measure of utility. There is growing debate relating to whether a QALY is the same regardless of who accrues it, and also the issue as to who should value health states. Research is required to further enhance the QALY approach to deal with challenges relating to equity-weighted utility maximization and testing the validity of underlying assumptions. Issues around choosing between condition-specific measures and generic instruments also merit further investigation.

Citing Articles

Cost Utility Analysis of Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder: Randomized Controlled Trial.

Zhou W, Chen Y, Wu H, Zhao H, Li Y, Shi G J Med Internet Res. 2025; 27:e67567.

PMID: 39970426 PMC: 11888078. DOI: 10.2196/67567.


Recovery trajectories after a serious injury or illness: a longitudinal evaluation of health-related quality of life in an Australian cohort.

Afoakwah C, Kuwornu P, Koomson I, Brain D, Xia Q, McPhail S Qual Life Res. 2025; .

PMID: 39960632 DOI: 10.1007/s11136-025-03919-w.


Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.

Abushanab D, Mohamed S, Abdel-Latif R, Moustafa D, Marridi W, Elazzazy S Clin Drug Investig. 2025; 45(3):151-163.

PMID: 39885055 PMC: 11876264. DOI: 10.1007/s40261-024-01413-8.


The international trial of nasal oxygen therapy after cardiac surgery (NOTACS) in patients at high risk of postoperative pulmonary complications: Economic evaluation protocol and analysis plan.

Shetty S, Duckworth M, Norman R, Affandi J, Dawson S, Fox-Rushby J PLoS One. 2025; 20(1):e0311861.

PMID: 39874369 PMC: 11774360. DOI: 10.1371/journal.pone.0311861.


Evaluating the Cost-Effectiveness of Antenatal Screening for Major Structural Anomalies During the First Trimester of Pregnancy: A Decision Model.

Campbell H, Karim J, Papageorghiou A, Wilson E, Rivero-Arias O BJOG. 2025; 132(5):638-647.

PMID: 39835406 PMC: 11879910. DOI: 10.1111/1471-0528.18053.